<DOC>
	<DOCNO>NCT01258062</DOCNO>
	<brief_summary>This double-blind , placebo control , safety immunogenicity study GelVac™ nasal powder H5N1 influenza vaccine . Healthy male female subject 18 49 year age eligible study participation enrol trial . It expect 10 subject screen obtain 7 subject eligible study participation . The primary objective determine frequency severity local systemic adverse event vaccine . The secondary objective ass immunogenicity vaccine base geometric mean titer ( GMT ) serum HAI , serum neutralizing , nasal wash IgA antibody .</brief_summary>
	<brief_title>Study Assess Safety Inactivated H5N1 Influenza Vaccine Administered GelVac Nasal Powder Healthy Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. able read sign Informed Consent Form ( ICF ) . 2. male female &gt; 18 &lt; 49 year age time ICF sign . 3. generally healthy , determined medical history clinical assessment . 4. able attend schedule visit comply trial procedure . 5. female childbearing potential , use acceptable method contraception abstinence least 4 week prior first vaccination least four week second vaccination . Acceptable method hormonal birth control barrier method spermicide . 6. female , post menopausal ( menstrual period within last 12 month ) , surgically sterile ( hysterectomy tubal ligation ) , negative urine pregnancy test within 24 hour prior time vaccination . 1. know allergy fruit ( e.g. , apple , orange ) pectin and/or pectin byproduct ( include jam jelly ) . 2. know allergy dairy/milk products/lactose . 3. breastfeed pregnant plan become pregnant within 1 month vaccination . 4. history chronic viral infection ( i.e . ; Shingles , Herpes Zoster , HIV ) . 5. history severe allergic reaction follow influenza vaccination , systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine contain substance . 6. history demyelinate disease ( esp . GuillianBarre Syndrome ) . 7. history Bell 's Palsy . 8. immunosuppression result underlie illness treatment . 9. use oral steroid , parenteral steroid , highdose inhaled steroid ( &gt; 800 µg/day beclomethasone dipropionate equivalent ) within 1 month prior vaccination . 10. use immunosuppressive cytotoxic drug radiation therapy within six month prior vaccination . 11. use OTC 'herbal ' immune suppressant stimulant within 6 month prior vaccination . 12. active neoplastic disease history hematologic malignancy past 5 year ( except localize skin prostate cancer stable absence therapy ) . 13. acute chronic condition ( opinion Investigator ) would render vaccination unsafe would interfere evaluation response include , limited following : know chronic liver disease , significant renal disease , oxygendependent chronic lung disease , New York Heart Association Functional Class III IV , unstable progressive neurologic disorder , insulintreated diabetes mellitus , asthma . 14. use experimental vaccine within 6 month prior study entry , expect use experimental vaccine entire study period inoculation study vaccine . 15. participation another clinical trial 30 day prior study entry . 16. use experimental device participation medical procedure trial within month prior study entry , expect use experimental device participation medical procedure trial entire study period . 17. receipt immunoglobulin blood product within 3 month prior enrollment . 18. receipt license vaccine within precede 6 month expect receive license vaccine within 28 day follow last trial vaccination . 19. subject enrol conflict clinical trial . 20. disorder therapy contraindicate influenza vaccination . 21 . Have clinically significant structural abnormality nasopharynx ( e.g. , obvious deviation obstruct airflow either nostril ) , determine investigator 22. acute respiratory disease time enrollment . 23. febrile illness temperature great equal 38 degree Celsius ( 100.4 degree F ) within 72 hour prior enrollment . 24. receipt allergy shot within precede 7 day expect receive allergy shot within 7 day follow vaccination . 25. condition , opinion investigator , would pose health risk participant . 26. presence active disease condition administration site , opinion Investigator , would impact vaccine delivery assessment vaccination site . 27. history drug abuse alcohol abuse five year prior enrollment . Subject abuse alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>